EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Unraveling resistance to immune checkpoint inhibitors in HNSCC: from mechanisms to combination therapies

Wenchao Zhao, Qingqing Luo, Bowen Yuan, Huaxin Duan, Siqing Jiang

Cancer Drug Resistance · 05.12.2025

DOI: 10.20517/cdr.2025.153 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Drug Resistance, online erschienen am 05.12.2025. Verfasst von Wenchao Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Hunan Provincial People's Hospital, the First Affiliated Hospital of Hunan Normal University, Changsha 410000, Hunan, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 187 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Head and neck squamous cell carcinoma (HNSCC), which arises from the mucosal linings of the oral cavity, pharynx, and larynx, represents the most prevalent head and neck malignancy. This cancer is notable for its elevated incidence and substantial mortality. The intricate anatomy of the region contributes to marked tumor heterogeneity, rendering the pursuit of effective therapeutic regimens a crucial aspect of enhancing clinical outcomes. Recently, the advent of immune checkpoint blockade, particularly agents targeting programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4, has introduced significant advancements within the oncological landscape, including for HNSCC. The introduction of immune checkpoint inhibitors, specifically the PD-1 blockers pembrolizumab and nivolumab, has established a new therapeutic standard for recurrent/metastatic HNSCC (R/M HNSCC). However, the clinical benefit is not universal, as a primary challenge remains the high incidence of treatment resistance. Consequently, a majority of patients (approximately 60%-70%) with R/M HNSCC derive minimal or no benefit from this form of immunotherapy, highlighting the critical need to understand the underlying resistance mechanisms. This review comprehensively discusses the types of immunotherapy resistance in HNSCC and the underlying mechanisms contributing to resistance. Furthermore, it reviews current strategies to overcome immunotherapy resistance, providing new perspectives for improving therapeutic efficacy in HNSCC.

Schlagwörter

Stichwörter der Autor:innen

PD-1R/M HNSCCimmunotherapytherapeutic strategiestherapy resistance

Autor:innen und Institutionen

  • Department of Oncology, Hunan Provincial People's Hospital, the First Affiliated Hospital of Hunan Normal University, Changsha 410000, Hunan, China.
  • Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, Changsha 410000, Hunan, China.
  • Hunan Hepatobiliary and Pancreatic Cancer Clinical Medical Research Center, Changsha 410000, Hunan, China.
  • Department of Pathology, the Third Xiangya Hospital of Central South University, Changsha 410013, Hunan, China.
  • Department of Comprehensive Chemotherapy/Head and Neck Cancer, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, Hunan, China.

Zitieren

APA

Zhao, W., Luo, Q., Yuan, B., Duan, H., & Jiang, S. (2025). Unraveling resistance to immune checkpoint inhibitors in HNSCC: from mechanisms to combination therapies. Cancer Drug Resistance. https://doi.org/10.20517/cdr.2025.153

Vancouver

Zhao W, Luo Q, Yuan B, Duan H, Jiang S. Unraveling resistance to immune checkpoint inhibitors in HNSCC: from mechanisms to combination therapies. Cancer Drug Resistance. 2025. doi:10.20517/cdr.2025.153

BibTeX
@article{Zhao2025,
  author = {Zhao, Wenchao and Luo, Qingqing and Yuan, Bowen and Duan, Huaxin and Jiang, Siqing},
  title = {Unraveling resistance to immune checkpoint inhibitors in HNSCC: from mechanisms to combination therapies},
  journal = {Cancer Drug Resistance},
  year = {2025},
  doi = {10.20517/cdr.2025.153}
}
Kostenlos starten →